Browse drugs

… with treatment-naïve, stage IV NSQ NSCLC without AGAs received STK-012 subcutaneously (SC) Q3W + standard of care pembrolizumab, pemet…

…arms (n=8,684 patients) with anti-PD-1/PD-L1 agents (nivolumab, pembrolizumab, atezolizumab, avelumab, durvalumab, cemiplimab) for adult soli…

…g immunosuppressive regimens comprising various combinations of sirolimus, everolimus, prednisone, cellcept, cyclosporine, tacrolimus, be…

…s (n=7, 47%), nivolumab/ipilimumab (n=3, 20%), atezolizumab and durvalumab (n=2 each, 13%), and cemiplimab and toripalimab (n=1 each, 7%) …

…by cemiplimab 350 mg IV on Day 5, or single-agent chemotherapy (vinorelbine, gemcitabine, or docetaxel). The primary endpoint is overall su…

…t for patients resistant to immune checkpoint inhibitors (ICI). Ateganosine (THIO; 6-thio-2’-deoxyguanosine) is recognized by telomerase an…

… due to the emergence of adverse events. An immunotherapy (IO), cemiplimab, was approved in patients with aBCC after failure or intoleranc…

…A1 clones. In this clinical case, we report a successful use of cemiplimab in a patient with VEXAS syndrome and a concomitant diagnosis of…

… experienced progressive disease on prior anti-PD-(L)1 therapy. Cavrotolimod, in combination with anti-PD-1 therapy, produced objective resp…